FI103337B1 - Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 2-okso-1H-atsepiinien valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 2-okso-1H-atsepiinien valmistamiseksi

Info

Publication number
FI103337B1
FI103337B1 FI932249A FI932249A FI103337B1 FI 103337 B1 FI103337 B1 FI 103337B1 FI 932249 A FI932249 A FI 932249A FI 932249 A FI932249 A FI 932249A FI 103337 B1 FI103337 B1 FI 103337B1
Authority
FI
Finland
Prior art keywords
azepines
oxo
preparation
therapeutically useful
useful substituted
Prior art date
Application number
FI932249A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI932249A0 (fi
FI932249L (fi
FI103337B (fi
Inventor
Donald S Karanewsky
Joel C Barrish
Jr Edward W Petrillo
Jeffrey A Robl
Denis E Ryono
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of FI932249A0 publication Critical patent/FI932249A0/fi
Publication of FI932249L publication Critical patent/FI932249L/fi
Application granted granted Critical
Publication of FI103337B publication Critical patent/FI103337B/fi
Publication of FI103337B1 publication Critical patent/FI103337B1/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • C07D211/76Oxygen atoms attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08Oxygen atoms
    • C07D223/10Oxygen atoms attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
FI932249A 1992-05-18 1993-05-18 Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 2-okso-1H-atsepiinien valmistamiseksi FI103337B1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88466492A 1992-05-18 1992-05-18
US88466492 1992-05-18

Publications (4)

Publication Number Publication Date
FI932249A0 FI932249A0 (fi) 1993-05-18
FI932249L FI932249L (fi) 1993-11-19
FI103337B FI103337B (fi) 1999-06-15
FI103337B1 true FI103337B1 (fi) 1999-06-15

Family

ID=25385092

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932249A FI103337B1 (fi) 1992-05-18 1993-05-18 Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 2-okso-1H-atsepiinien valmistamiseksi

Country Status (27)

Country Link
EP (2) EP0599444B1 (cs)
JP (1) JP3487611B2 (cs)
KR (2) KR100288722B1 (cs)
CN (1) CN1039008C (cs)
AT (1) ATE162800T1 (cs)
AU (2) AU659550B2 (cs)
BR (1) BR1101081A (cs)
CA (1) CA2096460C (cs)
CY (1) CY2093B1 (cs)
CZ (1) CZ289824B6 (cs)
DE (1) DE69316717T2 (cs)
DK (1) DK0599444T3 (cs)
ES (1) ES2111712T3 (cs)
FI (1) FI103337B1 (cs)
GR (1) GR3026665T3 (cs)
HU (1) HU217078B (cs)
IL (1) IL105729A (cs)
MX (1) MX9302876A (cs)
MY (1) MY111370A (cs)
NO (1) NO304372B1 (cs)
NZ (1) NZ247642A (cs)
PL (1) PL173036B1 (cs)
RU (1) RU2124503C1 (cs)
SG (1) SG54138A1 (cs)
SK (1) SK283556B6 (cs)
TW (1) TW290544B (cs)
ZA (1) ZA933461B (cs)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2078759C (en) * 1991-09-27 2003-09-16 Alan M. Warshawsky Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
US5455242A (en) * 1991-09-27 1995-10-03 Merrell Dow Pharmaceuticals Inc. Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace
DE69220744T2 (de) * 1991-09-27 1997-11-13 Merrell Pharma Inc 2-Substituierte Indan-2-Mercaptoacetylamid-Verbindungen mit Enkephalinase und ACE-Hemmwirkung
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5663166A (en) * 1991-10-18 1997-09-02 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
ATE164593T1 (de) * 1992-02-14 1998-04-15 Merrell Pharma Inc Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5420271A (en) * 1992-08-24 1995-05-30 Merrell Dow Pharmaceuticals, Inc. 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
GB9310075D0 (en) * 1993-05-17 1993-06-30 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
CA2140553A1 (en) * 1993-06-11 1994-12-22 Hitoshi Oinuma Amino acid derivative
ES2076096B1 (es) * 1993-07-14 1996-03-16 Squibb & Sons Inc Compuestos inhibidores de la enzima convertidora de angiotensinas y dela endopeptidasa neutra, y metodos para prepararlos.
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
JP3561753B2 (ja) * 1994-02-14 2004-09-02 メレル ファーマスーティカルズ インコーポレーテッド エンケファリナーゼ及びaceの阻害剤として有用な、新規な2−置換インダン−2−メルカプトアセチルアミドジスルフィド誘導体類
DK0745080T3 (da) * 1994-02-14 1999-09-27 Merrell Pharma Inc Nye mercaptoacetylamiddisulfidderivater, der er anvendelige som inhibitorer af enkephalinase og ACE.
NZ279396A (en) * 1994-02-14 1997-08-22 Merrell Pharma Inc Octahydro-6-hetring[2,1-a][2]benzazepine disulphide derivatives
CN1100785C (zh) * 1994-02-14 2003-02-05 默里尔药物公司 1,3,4,5-四氢苯并[c]氮杂䓬-3-酮二硫化物衍生物及方法
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
FI963783L (fi) * 1994-03-24 1996-09-23 Merrell Pharma Inc Hypokolesteroleemisiä, antiateroskleroottisia ja hypotriglyserideemisiä aminoasetyylimerkaptojohdannaisia
NZ282565A (en) * 1994-03-24 1999-11-29 Merrell Pharma Inc Condensed mercaptoacetylamidedisulphidebenzazepines used in treating elevated cholesterol levels, atherosclerosis, and hypotriglyceridemia
US5789403A (en) * 1994-07-18 1998-08-04 Eisai Co., Ltd. Substituted thiazolo 3,2-a!azepine derivatives
SI0800527T1 (en) * 1994-12-21 2000-08-31 Hoechst Marion Roussel, Inc. Novel processes for preparing intermediates of inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof
US5641880A (en) * 1994-12-21 1997-06-24 Hoechst Marion Roussel, Inc. Processes for preparing intermediates of inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof
CN1049830C (zh) * 1995-01-13 2000-03-01 李勤 一种治疗癌痛的热力敷
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5877313A (en) 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
JP3662257B2 (ja) * 1995-11-13 2005-06-22 エーザイ株式会社 コレステロール低下剤組成物
US6777550B1 (en) 1996-04-12 2004-08-17 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ACE inhibitors and/or NEP inhibitors
AU715451B2 (en) * 1996-04-12 2000-02-03 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or NEP inhibitors
US6117896A (en) 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
US6340752B1 (en) * 1998-01-06 2002-01-22 Bristol-Myers Squibb Co. Deprotection and recrystallization processes
EP1087775B1 (en) 1998-06-17 2005-08-17 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
US6770640B1 (en) 1998-12-31 2004-08-03 Aventis Pharmaceuticals Inc. 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
EP1150957A1 (en) * 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
US6262080B1 (en) 1998-12-31 2001-07-17 Avantis Pharmaceuticals Inc. 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase
WO2001055074A1 (en) 2000-01-25 2001-08-02 Kaneka Corporation Process for producing optically active carboxylic acid substituted in 2-position
US6509330B2 (en) 2000-02-17 2003-01-21 Bristol-Myers Squibb Company Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
DE10020818A1 (de) * 2000-04-28 2001-10-31 Degussa 2,6-Diamino-6-methyl-heptansäure und Derivate, Verfahren zu deren Herstellung und deren Verwendung
US7388098B2 (en) 2000-09-29 2008-06-17 Bristol-Myers Squibb Company Dynamic resolution of isomers and resolved isomers
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
CN1642550A (zh) 2002-02-14 2005-07-20 美瑞德生物工程公司 β-折叠模拟物和组合物及其有关方法
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US7045653B2 (en) 2002-12-23 2006-05-16 Pfizer, Inc. Pharmaceuticals
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1773348A4 (en) * 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8198311B2 (en) 2006-11-01 2012-06-12 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP4718534B2 (ja) * 2007-11-09 2011-07-06 カルピス株式会社 Fischer比低下抑制剤
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8106046B2 (en) 2008-06-24 2012-01-31 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
EP3177627B1 (en) 2014-08-07 2019-07-24 Intra-Cellular Therapies, Inc. Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one derivatives with pde1 inhibiting activity
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
CN106674228B (zh) * 2016-12-09 2018-12-04 河南农业大学 多元杂环化合物及其制备方法和用途
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規使用
PL4214210T3 (pl) * 2020-09-17 2025-08-18 Novartis Ag Związki i kompozycje jako inhibitory sppl2a

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4339600A (en) 1976-05-10 1982-07-13 E. R. Squibb & Sons, Inc. Compounds for alleviating angiotensin related hypertension
US4629787A (en) 1980-08-18 1986-12-16 Merck & Co., Inc. Substituted caprolactam derivatives as antihypertensives
US4587050A (en) 1980-08-18 1986-05-06 Merck & Co., Inc. Substituted enantholactam derivatives as antihypertensives
US4415496A (en) 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
US4587238A (en) 1981-07-06 1986-05-06 Merck & Co., Inc. Substituted caprylolactam derivatives as anti-hypertensives
EP0094283B1 (fr) 1982-05-04 1985-11-21 Lipha, Lyonnaise Industrielle Pharmaceutique Forme médicamenteuse de théophylline à action prolongée
US4873235A (en) 1982-06-01 1989-10-10 Merck & Co., Inc. Benzofused lactams as antihypertensives
US4473575A (en) 1982-07-19 1984-09-25 Ciba-Geigy Corporation 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids
US4465679A (en) 1983-01-31 1984-08-14 Usv Pharmaceutical Corporation 1,2-Diaza-3-one compounds, their use in treating hypertension and pharmaceutical compositions thereof
US4470988A (en) 1983-02-10 1984-09-11 Ciba-Geigy Corporation Benzazocinone and benzazoninone derivatives, and their pharmaceutical use
US4477464A (en) 1983-02-10 1984-10-16 Ciba-Geigy Corporation Hetero-benzazepine derivatives and their pharmaceutical use
US4711884A (en) 1983-02-28 1987-12-08 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
US4460579A (en) 1983-02-28 1984-07-17 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
US4617301A (en) 1983-06-22 1986-10-14 Merck & Co., Inc. Sulfoxide and sulfone derivatives of bicyclic lactams as antihypertensives
US4539150A (en) 1983-06-29 1985-09-03 Mitsui Toatsu Chemicals, Inc. Benzothiazepine derivatives and their methods of preparation
IL72523A (en) 1983-08-12 1988-06-30 Takeda Chemical Industries Ltd 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them
DE3402310A1 (de) 1984-01-24 1985-07-25 Bayer Ag, 5090 Leverkusen Harte, geschlossenzellige, flammfeste polyurethanschaumstoffe
US4699905A (en) 1984-04-10 1987-10-13 Sankyo Company, Limited Perhydrothiazepine derivatives, their preparation and their therapeutic use
JPH0637473B2 (ja) 1985-10-11 1994-05-18 三共株式会社 ラクタム化合物
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4801609B1 (en) 1987-03-27 1993-11-09 Mercapto-acylamino acid antihypertensives
US4767756A (en) * 1987-07-17 1988-08-30 E. R. Squibb & Sons, Inc. 3-substituted benzazepines
US4771047A (en) * 1987-07-27 1988-09-13 E. R. Squibb & Sons, Inc. Benzazepine derivatives
JP3054738B2 (ja) * 1988-07-22 2000-06-19 武田薬品工業株式会社 チアゾロ[5,4―b]アゼピン誘導体
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace

Also Published As

Publication number Publication date
EP0599444A1 (en) 1994-06-01
DE69316717T2 (de) 1998-08-27
CZ289824B6 (cs) 2002-04-17
FI932249A0 (fi) 1993-05-18
KR100277453B1 (ko) 2000-12-15
MY111370A (en) 1999-12-31
SK283556B6 (sk) 2003-09-11
MX9302876A (es) 1993-12-01
PL298988A1 (en) 1994-01-24
GR3026665T3 (en) 1998-07-31
FI932249L (fi) 1993-11-19
AU674629B2 (en) 1997-01-02
KR100288722B1 (ko) 2001-05-02
HUT68391A (en) 1995-06-28
DK0599444T3 (da) 1998-09-21
JPH0656790A (ja) 1994-03-01
CZ93693A3 (en) 1993-12-15
JP3487611B2 (ja) 2004-01-19
KR930023349A (ko) 1993-12-18
AU2852595A (en) 1995-10-19
IL105729A (en) 1998-01-04
FI103337B (fi) 1999-06-15
TW290544B (cs) 1996-11-11
CA2096460C (en) 2004-03-16
ZA933461B (en) 1993-12-14
CA2096460A1 (en) 1993-11-19
EP0783002A2 (en) 1997-07-09
ATE162800T1 (de) 1998-02-15
NO304372B1 (no) 1998-12-07
CN1084849A (zh) 1994-04-06
HK1003597A1 (en) 1998-10-30
RU2124503C1 (ru) 1999-01-10
AU659550B2 (en) 1995-05-18
CN1039008C (zh) 1998-07-08
DE69316717D1 (de) 1998-03-05
IL105729A0 (en) 1993-09-22
NZ247642A (en) 1995-09-26
PL173036B1 (pl) 1998-01-30
NO931795D0 (no) 1993-05-18
EP0783002A3 (en) 1997-07-30
HU9301448D0 (en) 1993-09-28
ES2111712T3 (es) 1998-03-16
AU3862793A (en) 1993-11-25
SG54138A1 (en) 1998-11-16
EP0599444B1 (en) 1998-01-28
NO931795L (no) 1993-11-19
HU217078B (hu) 1999-11-29
SK49993A3 (en) 1994-08-10
BR1101081A (pt) 2000-03-28
CY2093B1 (en) 2002-04-05

Similar Documents

Publication Publication Date Title
FI103337B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 2-okso-1H-atsepiinien valmistamiseksi
NO178969C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte kinazolinoner
NO180718C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive mercaptoacetylamidderivater
DE3378052D1 (en) Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
FI906438A0 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten A-nor-steroidi-3-karboksyylihappojohdannaisten valmistamiseksi
FI883064A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
NO179448C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive forbindelser
HUT40331A (en) Process for preparing pharmaceutical compositions containing a combination of dihidro-pyridines and ace-inhibitors
FR2700538B1 (fr) Procédé de préparation de 2-méthyl-3-aminobenzotrifluorure.
FR2710339B1 (fr) Procédé de préparation de fuchsones.
MA21068A1 (fr) Procede de preparation d'une composition a base d'inhibiteur de l'enzyme de conversion de l'angiotensine .
DE3464915D1 (en) (5-(2-aminomethyl-imidazol-1-yl)-1,3-dialkyl-1h-pyrazol-4-yl)(aryl)methanones and processes for their production
FR2695639B1 (fr) Procédé de préparation des N-(méth)acryloyl carbamates.
PT73948A (en) Process for the preparation of biologically active heterobicyclic hydroximidates and thiolhydroximidates and carbamate ester derivatives thereof
FR2700334B1 (fr) Procédé de préparation de fuchsones.
EP0628634A3 (en) Process for the preparation of serine hydromethyltransferase.